Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648634 | 0.92 | C5AR1 (0.53) | C5AR1SMN1; SMN2LMNAL3MBTL1GBA1 | |
| SCHEMBL649257 | 0.92 | C5AR1 (0.56) | C5AR1SMN1; SMN2LMNAL3MBTL1GBA1 | |
| SCHEMBL652376 | 0.91 | C5AR1 (0.58) | C5AR1SMN1; SMN2LMNAL3MBTL1GBA1 | |
| SCHEMBL649839 | 0.88 | C5AR1 (0.53) | C5AR1SMN1; SMN2LMNAL3MBTL1GBA1 | |
| SCHEMBL650504 | 0.88 | C5AR1 (0.53) | C5AR1SMN1; SMN2LMNAL3MBTL1GBA1 | |
| SCHEMBL1912840 | 0.88 | C5AR1 (0.63) | C5AR1SMN1; SMN2LMNAL3MBTL1GBA1 | |
| SCHEMBL651344 | 0.88 | C5AR1 (0.51) | C5AR1SMN1; SMN2LMNAL3MBTL1GBA1 | |
| SCHEMBL650416 | 0.88 | C5AR1 (0.52) | C5AR1SMN1; SMN2LMNAL3MBTL1GBA1 | |
| SCHEMBL650038 | 0.88 | C5AR1 (0.52) | C5AR1SMN1; SMN2LMNAL3MBTL1GBA1 | |
| SCHEMBL650515 | 0.87 | C5AR1 (0.54) | C5AR1SMN1; SMN2LMNAL3MBTL1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115403527-A | Method for synthesizing bactericide ethirimol by reductive amination method | 西安近代化学研究所 | 2022-11-29 | — | — | CN | claimed |
| CN-114933532-A | Method for continuously synthesizing 2-n-butyl ethyl acetoacetate by using fixed bed | 安徽英瑞骐生物科技有限公司 | 2022-08-23 | — | — | CN | claimed |
| CN-114920646-A | Novel synthesis method of 2-n-butyl ethyl acetoacetate | 安徽英瑞骐生物科技有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-114933532-B | Method for continuously synthesizing 2-n-butyl acetoacetic acid ethyl ester by fixed bed | 安徽英瑞骐生物科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-115403527-A | Method for synthesizing bactericide ethirimol by reductive amination method | 西安近代化学研究所 | 2022-11-29 | — | — | CN | disclosed |
| CN-114933532-A | Method for continuously synthesizing 2-n-butyl ethyl acetoacetate by using fixed bed | 安徽英瑞骐生物科技有限公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-114920646-A | Novel synthesis method of 2-n-butyl ethyl acetoacetate | 安徽英瑞骐生物科技有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1742924-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005108376-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1490343-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1479681-A1 | IMIDAZO(1,2-a)PYRIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-20040116424-A1 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION | 2004-06-17 | — | — | US | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003082829-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | MANBA, MAN2B1, ERG28 | C5AR1 4363/4885SMN1; SMN2 2642/4885LMNA 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.